Publications & Posters
Scholary publications
Spinal Muscular Atrophy
Apitegromab
September 2020
World Muscle Society
Clinical Development of SRK-015,a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
June 2020
CURE SMA Annual Conference
Clinical Development of SRK-015 for the Treatment of Later-Onset Spinal Muscular Atrophy
Spinal Muscular Atrophy
Apitegromab
June 2020
CURE SMA Annual Conference
Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ)
Spinal Muscular Atrophy
Apitegromab
May 2020
American Academy of Neurology Conference
A Phase 2 Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy (TOPAZ): An Introduction
Spinal Muscular Atrophy
Apitegromab
April 2020
Journal of Biological Chemistry
Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
Immuno-Oncology
SRK-181
March 2020
Science Translational Medicine
